Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
7
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
fda
gene therapy
abbvie
biogen
alnylam pharmaceuticals
amgen
astrazeneca
bristol-myers squibb
cancer
cancer immunotherapy
deals
What
bio
7
×
roundup
7
×
days
democrats
drug
ipo
new
news
abbvie’s
acquisitions
advantages
ahead
alzheimer’s
america
announced
approval
august
bar
biofourmis
biogen
biogen’s
biopharmaceutical
biotech
brings
bucks
busy
cancer
celebrate
ceo
chance
collabs
companies
congress
continues
convo
convoluted
corner
covid
daniel
day
Language
unset
Current search:
roundup
×
novartis
×
" clinical trials "
×
" indiana blog main "
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel